Peter Greenleaf, Aurinia CEO

Au­rinia faces chop­py wa­ters amid low­er-than-ex­pect­ed 2022 guid­ance and patent chal­lenge on Lup­ky­nis

A new patent chal­lenge to Au­rinia Phar­ma­ceu­ti­cals’ lu­pus nephri­tis drug Lup­ky­nis is adding to the bio­phar­ma’s woes this week. Sun Phar­ma­ceu­ti­cal is chal­leng­ing Au­rinia’s “treat­ment pro­to­col” patent, the com­pa­ny re­vealed in a 10-K fil­ing this week first re­port­ed by STAT.

Au­rinia pushed back on the news re­port, point­ing out, in a state­ment to End­points News, that the patent has al­ready been through “sig­nif­i­cant re­view” with the US Patent and Trade­mark Of­fice be­fore Lup­ky­nis was ap­proved by the FDA in Jan­u­ary 2021.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.